The State of Clinical Trials in Pediatric Inflammatory Bowel Disease.
Gastroenterol Clin North Am
; 52(3): 589-597, 2023 09.
Article
em En
| MEDLINE
| ID: mdl-37543402
ABSTRACT
The gap between available biologic and small molecule therapy for inflammatory bowel disease for children and adults remains large. At present only 2 anti-TNF agents are licensed for pediatric use compared with multiple other agents with different mechanisms of action being used in adults. The reasons are many but largely revolve around the inadequate acceptance of adult efficacy data to children, and the reluctance of industry to commit to early pediatric drug development for fear of inadequate return on investment. We suggest common sense steps that need to be taken to improve this situation.
Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Doenças Inflamatórias Intestinais
/
Colite Ulcerativa
/
Doença de Crohn
Idioma:
En
Ano de publicação:
2023
Tipo de documento:
Article